The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Interferon Abbreviations: FDA, U.S. Food and Drug Administration; HBV, hepatitis B virus. For the past 5 years, Dr. Calvin Q. Pan has received research grants from Gilead, Bristol Myers Squibb ...

Fortunately, treatment options that were limited when she first began working in this area in 2008 have also since changed. These days her research is focused on driving the availability of data ...

Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny. In the year-ago quarter, ...